[go: up one dir, main page]

AU1154195A - Intermediates useful in the preparation of indoline derivatives carrying an amide functional group - Google Patents

Intermediates useful in the preparation of indoline derivatives carrying an amide functional group

Info

Publication number
AU1154195A
AU1154195A AU11541/95A AU1154195A AU1154195A AU 1154195 A AU1154195 A AU 1154195A AU 11541/95 A AU11541/95 A AU 11541/95A AU 1154195 A AU1154195 A AU 1154195A AU 1154195 A AU1154195 A AU 1154195A
Authority
AU
Australia
Prior art keywords
alkyl
mono
substd
halogen
opt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU11541/95A
Other versions
AU691223B2 (en
Inventor
Dino Nisato
Claude Plouzane
Claudine Serradeil-Le Gal
Bernard Tonnerre
Jean Wagnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU1154195A publication Critical patent/AU1154195A/en
Assigned to SANOFI reassignment SANOFI Amend patent request/document other than specification (104) Assignors: ELF SANOFI
Application granted granted Critical
Publication of AU691223B2 publication Critical patent/AU691223B2/en
Assigned to SANOFI-SYNTHELABO reassignment SANOFI-SYNTHELABO Request to Amend Deed and Register Assignors: SANOFI
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

3-Hydroxy-1-indolinyl sulphones of formula (I) and their salts are new: In (I), R1 = halogen, 1-4C alkyl, OH, 1-4C alkoxy, benzyloxy, CN, CF3, NO2 or NH2; R2 = 1-6C alkyl; 3-7C cycloalkyl,; 5-7C cycloalkenyl; phenyl opt. substd. by 1-4C alkyl, 1-4C alkoxy, halogen, CF3 and/or NH2; or nitrophenyl opt. substd. by CF3, 1-4C alkyl or halogen; R5 = 1-4C alkyl; 1- or 2-naphthyl;5-dimethylamino-1-naphthyl; phenyl opt. substd. by halogen, CF3, NH2, mono- or di (1-4C alkyl) amino, OH, 1-4C alkoxy, 2-4C alkenyloxy, 1-4C alkylthio, CF3, benzyloxy, CN, COOH, 2-5C alkoxycarbonyl, CONH2, mono- or di (1-4C alkyl)carbamoyl or 1-4C alkanoylamino; or nitrophenyl opt. substd. by CF3, 2-4C alkenyloxy, halogen, 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio, OCF3 or benzyloxy; R6 = 1-6C alkyl or R7; R7 = 1-R-4-piperidinyl, 1-R-3-azetidinyl or (CH2)rR'; R = H, 1-4C alkyl, benzyloxycarbonyl or 2-5C alkoxycarbonyl; R1 = pyridyl, OH, NH2, mono- or di(1-4C alkyl)amino, COOH, 2-5C alkoxycarbonyl, benzylcarbonyl, CONH2 or mono- or di(1-4C alkyl)carbamoyl; or NR6R7 = morpholino; thiomorpholino; thiazolidinyl or 2,2-dimethylthiazolidinyl opt. substd. by R8; 1-piperazinyl opt. 4-substd. by R"8; and unsatd. 5-membered monoaza ring substd. by R8; or a satd. 3- to 7-membered monoaza ring substd. by R8 and R9; R8 = R'8 or (CH2)rA1, where A1 = OH, NH2 or mono- or di(1-4C alkyl)amino; R'8 = (CH2)qA2, where A2 = COOH, 2-5C alkoxycarbonyl, benzyloxycarbonyl, CONH2, CONHOH, mono- or di(1-4C alkyl)carbamoyl, CSNH2 or mono- or di(1-4C alkyl)thiocarbamoyl; R"8 = R8' or (CH2)A3, where A3 = NH2 or mono- or di(1-4C alkyl)amino; R9 = H, halogen, (CH2rOR10), (CH2)rNR11R12, (CH2)SCONR11R'11 or N3; R10 = H, 1-4C alkyl, mesyl or tosyl; R11, R'11 and R12 = H or 1-4C alkyl, or R11 = H, and R12 = benzyloxycarbonyl or 2-5C alkoxycarbonyl; n and m = 0-2; q = 0-3; r = 0-3, but not 0 when R8 or R9 is in a position alpha to the intracyclic amidic nitrogen (SiC); s = 0 or 1.
AU11541/95A 1991-08-02 1995-02-03 Intermediates useful in the preparation of indoline derivatives carrying an amide functional group Ceased AU691223B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9109908 1991-08-02
FR9109908A FR2679903B1 (en) 1991-08-02 1991-08-02 DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU24758/92A Division AU658664B2 (en) 1991-08-02 1992-07-31 Indoline derivatives having an amide function, their preparation, and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
AU1154195A true AU1154195A (en) 1995-05-04
AU691223B2 AU691223B2 (en) 1998-05-14

Family

ID=9415909

Family Applications (2)

Application Number Title Priority Date Filing Date
AU24758/92A Ceased AU658664B2 (en) 1991-08-02 1992-07-31 Indoline derivatives having an amide function, their preparation, and pharmaceutical compositions containing them
AU11541/95A Ceased AU691223B2 (en) 1991-08-02 1995-02-03 Intermediates useful in the preparation of indoline derivatives carrying an amide functional group

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU24758/92A Ceased AU658664B2 (en) 1991-08-02 1992-07-31 Indoline derivatives having an amide function, their preparation, and pharmaceutical compositions containing them

Country Status (28)

Country Link
EP (1) EP0526348B1 (en)
JP (1) JP2633085B2 (en)
KR (1) KR100241583B1 (en)
AT (1) ATE163289T1 (en)
AU (2) AU658664B2 (en)
BR (1) BR9205336A (en)
CA (2) CA2206776C (en)
CZ (1) CZ288173B6 (en)
DE (1) DE69224450T2 (en)
DK (1) DK0526348T3 (en)
ES (1) ES2117038T3 (en)
FI (2) FI104069B1 (en)
FR (1) FR2679903B1 (en)
HU (2) HUT68927A (en)
IL (3) IL117592A (en)
LT (1) LT3064B (en)
LV (1) LV10091B (en)
MX (1) MX9204487A (en)
MY (1) MY110517A (en)
NO (1) NO180047C (en)
NZ (1) NZ243795A (en)
PH (1) PH30661A (en)
RU (1) RU2104268C1 (en)
SG (1) SG47501A1 (en)
SK (1) SK283463B6 (en)
UA (1) UA27238C2 (en)
WO (1) WO1993003013A1 (en)
ZA (1) ZA925781B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR2708608B1 (en) * 1993-07-30 1995-10-27 Sanofi Sa N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them.
FR2756736B1 (en) * 1996-12-05 1999-03-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES
HUP0003921A3 (en) * 1997-07-31 2001-03-28 Wyeth Corp Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
PL338506A1 (en) * 1997-07-31 2000-11-06 Elan Pharm Inc Compounds inhibiting adhesion of leucocytes occuring through the mediation of vla-4
HUP0002495A3 (en) * 1997-07-31 2001-01-29 American Home Prod Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2775598A1 (en) * 1998-03-06 1999-09-10 Sanofi Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS
FR2778103A1 (en) * 1998-04-29 1999-11-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST
FR2786486B3 (en) * 1998-11-16 2000-12-08 Sanofi Sa PROCESS FOR THE PREPARATION OF (2S) -1 - [(2R, 3S) -5-CHLORO-3- (2- CHLOROPHENYL) -1- (3,4-DIMETHOXY BENZENESULFONYL) -3-HYDROXY- 2,3-DIHYDRO- 1H-INDOLE-2-CARBONYL] PYRROLIDINE-2-CARBOXAMIDE, ITS SOLVATES AND / OR HYDRATES
PL350050A1 (en) 1999-01-22 2002-10-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
EP1147091A2 (en) 1999-01-22 2001-10-24 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
MXPA01007394A (en) * 1999-01-25 2002-04-09 Wyeth Corp Compounds which inhibit leukocyte adhesion mediated by vla-4.
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
FR2792834A1 (en) * 1999-04-29 2000-11-03 Sanofi Sa USE OF SR 49059, ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES AND / OR HYDATES FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF RAYNAUD PHENOMENON
FR2805536B1 (en) * 2000-02-25 2002-08-23 Sanofi Synthelabo NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2805992A1 (en) * 2000-03-08 2001-09-14 Sanofi Synthelabo Oral administration of N-sulfonyl-indoline derivative to treat central nervous system, cardiovascular or gastric disorders, using polyethylene glycol, polysorbate and poloxamer as solubilizers for high bioavailability
IL155333A0 (en) 2000-10-17 2003-11-23 Applied Res Sulfanilide derivatives for use in medicine, certain such new derivatives and their preparation
CA2425892A1 (en) 2000-11-28 2003-04-11 Hiroyuki Koshio 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivative or salt thereof
JP4044740B2 (en) * 2001-05-31 2008-02-06 信越化学工業株式会社 Resist material and pattern forming method
IL162615A0 (en) 2001-12-20 2005-11-20 Applied Research Systems Triazole derivatives, their preparation and pharmaceutical compositions containing them
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CA2485681C (en) 2002-05-24 2012-10-16 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
CA2498946A1 (en) * 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag 2,4-substituted indoles and their use as 5-ht6 modulators
ATE362469T1 (en) * 2002-09-17 2007-06-15 Hoffmann La Roche 2,7-DISUBSTITUTEDINDOLES AND THEIR USE AS 5-HT6 MODULATORS
JP4528125B2 (en) * 2002-10-11 2010-08-18 アクテリオン ファーマシューティカルズ リミテッド Sulfonylamino-acetic acid derivatives
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
ATE363470T1 (en) 2002-11-18 2007-06-15 Chemocentryx Inc ARYLSULFONAMIDE
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
JP5049013B2 (en) * 2004-10-27 2012-10-17 キッセイ薬品工業株式会社 Indoline compound and method for producing the same
KR20080059268A (en) 2005-09-29 2008-06-26 엘란 파마슈티칼스, 인크. Pyrimidinyl amide compounds that inhibit leukocyte adhesion mediated by JLA-4
ATE502031T1 (en) 2005-09-29 2011-04-15 Elan Pharm Inc CARBAMAT COMPOUNDS THAT INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
TWI389904B (en) 2006-02-27 2013-03-21 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
EP2424841A1 (en) 2009-04-27 2012-03-07 Elan Pharmaceuticals Inc. Pyridinone antagonists of alpha-4 integrins
HU231206B1 (en) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
TW202542165A (en) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 Macrocyclic orexin agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (en) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl derivatives, processes for their preparation, and their use as medicaments
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Also Published As

Publication number Publication date
FI980175L (en) 1998-01-27
FI980175A0 (en) 1998-01-27
HK1008741A1 (en) 1999-05-14
EP0526348A1 (en) 1993-02-03
SK283463B6 (en) 2003-08-05
EP0526348B1 (en) 1998-02-18
DE69224450T2 (en) 1998-07-30
FR2679903A1 (en) 1993-02-05
IL117592A (en) 1999-04-11
MY110517A (en) 1998-07-31
HUT68927A (en) 1995-08-28
IL117592A0 (en) 1996-07-23
WO1993003013A1 (en) 1993-02-18
CA2206776A1 (en) 1993-02-03
NZ243795A (en) 1995-04-27
ES2117038T3 (en) 1998-08-01
KR100241583B1 (en) 2000-03-02
NO180047C (en) 1997-02-05
JP2633085B2 (en) 1997-07-23
ZA925781B (en) 1993-03-02
MX9204487A (en) 1993-02-01
CZ288173B6 (en) 2001-05-16
DE69224450D1 (en) 1998-03-26
SK42693A3 (en) 1993-10-06
FI104069B (en) 1999-11-15
NO931262D0 (en) 1993-04-01
SG47501A1 (en) 1998-04-17
LV10091A (en) 1994-05-10
LTIP114A (en) 1994-06-15
DK0526348T3 (en) 1998-11-23
FI931476A0 (en) 1993-04-01
NO180047B (en) 1996-10-28
IL102703A0 (en) 1993-01-14
HU211884A9 (en) 1995-12-28
FI104069B1 (en) 1999-11-15
JPH06501960A (en) 1994-03-03
CA2093221A1 (en) 1993-02-03
FI107048B (en) 2001-05-31
AU691223B2 (en) 1998-05-14
RU2104268C1 (en) 1998-02-10
AU658664B2 (en) 1995-04-27
FR2679903B1 (en) 1993-12-03
UA27238C2 (en) 2000-08-15
PH30661A (en) 1997-09-16
ATE163289T1 (en) 1998-03-15
NO931262L (en) 1993-05-26
LT3064B (en) 1994-10-25
LV10091B (en) 1995-04-20
IL102703A (en) 1997-03-18
BR9205336A (en) 1993-11-16
CA2206776C (en) 2002-02-26
HU9300951D0 (en) 1993-06-28
FI931476A7 (en) 1993-04-01
CA2093221C (en) 1998-09-22
AU2475892A (en) 1993-03-02
CZ68293A3 (en) 1994-01-19

Similar Documents

Publication Publication Date Title
AU691223B2 (en) Intermediates useful in the preparation of indoline derivatives carrying an amide functional group
PT81748A (en) Process for the preparation of novel oxetanones of novel intermediates which are usable in this process and of pharmaceutical compositions based on said oxetanones or based on precursors thereof
IL110820A0 (en) N-substituted heterocyclic derivatives and their preparation
NZ325837A (en) Carbamoyloxy derivatives of mutiline and their use as antibacterials
HUP9901630A2 (en) Novel indole-2,3-dione-3-oxime derivatives
NZ333926A (en) Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
AU9426098A (en) Azetidinone derivatives for the treatment of hcmv infections
DE3783657D1 (en) PEPTIDES WITH INFLUENCE ON DIURESE AND NATURALSE, METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS THEREOF AND THEIR USE.
GB1447426A (en) Pyrrolo 3,4-d- pyrimidines and methods for their preparation
ES8607910A1 (en) Tertiary amines.
ES341317A1 (en) Novel Pyrazinamides and their Preparation
HUP9902606A2 (en) Matrix metalloproteinase inhibitors
GB1505848A (en) 3,4-dicarboxycephalosporins and derivatives
GB1488411A (en) 3,4-dihydro-4-arylquinolin-4-ol derivatives
ES454313A1 (en) Furotriazines
IL99819A0 (en) Imidazole-2-yl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
ES8404362A1 (en) 7-Hydroxy-imino-amino-thiadiazolyl -acetamido-3-cephem derivs.

Legal Events

Date Code Title Description
HB Alteration of name in register

Free format text: SANOFI-SYNTHELABO